Fulgent Genetics Reports Strong Q3 2024 Results
In This Article:
Fulgent Genetics ( (FLGT) ) has provided an announcement.
Fulgent Genetics reported third-quarter 2024 financial results, showcasing a total revenue of $71.7 million with a 9% year-over-year growth in core revenue. While the company faced a GAAP loss of $14.6 million, it achieved a non-GAAP income of $9.4 million. Fulgent remains optimistic about its full-year core revenue guidance of $280 million and improved earnings per share. The company continues to advance its laboratory services and therapeutic development, particularly in cancer treatment trials, while maintaining strong cash reserves.
Learn more about FLGT stock on TipRanks’ Stock Analysis page.